ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > APRIL

APRIL

概要

Name:Tumor necrosis factor ligand superfamily member 13
Target Synonym:Tumor Necrosis Factor Ligand 7B,CD256 Antigen,TNLG7B,CD256,TNF- and APOL-related leukocyte expressed ligand 2,TNFSF13,TNF-related death ligand 1,ZTNF2,TALL-2,APRIL,Tumor necrosis factor ligand superfamily member 13,TNF Superfamily Member 13,Tumor Necrosis Factor (Ligand) Superfamily, Member 13,TRDL-1,TALL2,Tumor Necrosis Factor Superfamily Member 13,Tumor Necrosis Factor-Like Protein ZTNF2,UNQ383/PRO715,A Proliferation-Inducing Ligand,Tumor Necrosis Factor-Related Death Ligand-1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
APL-H5263 Human Human APRIL / TNFSF13 Protein, Fc Tag, active trimer
APL-H5263-structure
APL-H5263-sds
APL-H82Q8 Human Biotinylated Human APRIL / TNFSF13 Protein, Avitag™,His Tag, active trimer (MALS verified)
APL-H82Q8-sds
APL-C52D2 Cynomolgus Cynomolgus APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified)
APL-C52D2-sds
APL-H52D1 Human Human APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified)
APL-H52D1-sds
APL-H82F5 Human Biotinylated Human APRIL / TNFSF13 Protein, Fc,Avitag™
APL-H82F5-structure
APL-H82F5-sds
ACRO Quality

生物活性データの一部

APL-H52D1-BLI
APRIL BLI

Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with an affinity constant of 1.88 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
APL-H52D1-BLI
APRIL BLI

Loaded Human APRIL Protein, His,Flag Tag (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human TACI Protein, Fc Tag with an affinity constant of 75 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

Synonym Name

APRIL,TNFSF13,TALL-2,TRDL-1,CD256,TALL2,ZTNF2

Background

APRIL(a proliferation-inducing ligand) is also known as Tumor necrosis factor ligand superfamily member 13, TALL-2, TRDL-1, CD256, TNFFSF 13, cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. APRIL is a cytokine of the tumor necrosis factor family associated mainly with hematologic malignancies. The closely related TNF family ligands B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serve in the generation and maintenance of mature B-lymphocytes. Both BAFF and APRIL assemble as homotrimers that bind and activate several receptors that they partially share. BAFF-APRIL heteromers of different stoichiometries have distinct receptor-binding properties and activities. In addition, expression of APRIL was regulated by miR-145 in GC cells.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Telitacicept RCT-18; RC-18; RCT18; RC18 Approved RemeGen Co Ltd 泰爱 Mainland China Lupus Erythematosus, Systemic RemeGen Co Ltd 2021-03-09 Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Sjogren's Syndrome; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic Details
Telitacicept RCT-18; RC-18; RCT18; RC18 Approved RemeGen Co Ltd 泰爱 Mainland China Lupus Erythematosus, Systemic RemeGen Co Ltd 2021-03-09 Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Sjogren's Syndrome; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Atacicept TACI-Ig Phase 3 Clinical Zymogenetics Inc Glomerulonephritis, IGA; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Optic Neuritis; Lupus Erythematosus, Systemic Details
Zigakibart BION-1301 Phase 3 Clinical Aduro Biotech Inc Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma Details
Sibeprenlimab VIS-649 Phase 3 Clinical Visterra Inc Glomerulonephritis, IGA; Glomerulonephritis Details
Povetacicept ALPN-303; ALPN 30x Phase 2 Clinical Alpine Immune Sciences Inc Purpura, Thrombocytopenic, Idiopathic; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Lupus Nephritis; Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) Phase 1 Clinical Eugia Pharma Specialities Ltd, Actavis Inc Multiple Myeloma Details
anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital） Phase 1 Clinical Massachusetts General Hospital Multiple Myeloma Details
AUR-200 AUR-200; AUR200 Phase 1 Clinical Thunderbolt Pharma Inc Autoimmune Diseases Details
RO-7297089 RO-7297089; AFM-26; RG-6296 Phase 1 Clinical Genentech Inc Multiple Myeloma Details
APRIL CAR-T Cell therapy (Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) Clinical Huazhong University Of Science And Technology Multiple Myeloma Details
Atacicept TACI-Ig Phase 3 Clinical Zymogenetics Inc Glomerulonephritis, IGA; Arthritis, Rheumatoid; Multiple Sclerosis; Lupus Nephritis; Optic Neuritis; Lupus Erythematosus, Systemic Details
Zigakibart BION-1301 Phase 3 Clinical Aduro Biotech Inc Glomerulonephritis, IGA; Proteinuria; Multiple Myeloma Details
Sibeprenlimab VIS-649 Phase 3 Clinical Visterra Inc Glomerulonephritis, IGA; Glomerulonephritis Details
Povetacicept ALPN-303; ALPN 30x Phase 2 Clinical Alpine Immune Sciences Inc Purpura, Thrombocytopenic, Idiopathic; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Lupus Nephritis; Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) Phase 1 Clinical Eugia Pharma Specialities Ltd, Actavis Inc Multiple Myeloma Details
anti-TriPRIL CAR T-cell therapy（Massachusetts General Hospital） Phase 1 Clinical Massachusetts General Hospital Multiple Myeloma Details
AUR-200 AUR-200; AUR200 Phase 1 Clinical Thunderbolt Pharma Inc Autoimmune Diseases Details
RO-7297089 RO-7297089; AFM-26; RG-6296 Phase 1 Clinical Genentech Inc Multiple Myeloma Details
APRIL CAR-T Cell therapy (Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) Clinical Huazhong University Of Science And Technology Multiple Myeloma Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap